^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2)

    i
    Other names: PLOD2, Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 2, Procollagen-Lysine 5-Dioxygenase, Lysyl Hydroxylase 2, Lysyl Hydroxlase 2, LH2, Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase (Lysine Hydroxylase) 2, Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 2, Telopeptide Lysyl Hydroxylase, Lysine Hydroxylase 2, BRKS2, TLH
    10d
    Whole-Transcriptome Analysis of Gene Expression in Canine Splenic Lymphoid Hyperplasia, Complex Hyperplasia, Histiocytic Sarcoma, and Stromal Sarcoma. (PubMed, Animals (Basel))
    These findings suggest that dysregulated gene expression may contribute to the activation of stromal cells and macrophages within the spleen, facilitating malignant transformation. Overall, these findings deliver novel transcriptomic insights into canine splenic tumorigenesis that may improve diagnostic precision, inform prognostic assessment, and support the development of targeted therapeutic strategies in veterinary oncology.
    Journal
    |
    NOTCH3 (Notch Receptor 3) • CSF1 (Colony stimulating factor 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • MRC1 (Mannose Receptor C-Type 1) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • COL12A1 (Collagen Type XII Alpha 1 Chain) • COL4A1 (Collagen Type IV Alpha 1 Chain) • SLC40A1 (Solute Carrier Family 40 Member 1)
    28d
    Hypoxia-Driven Immune Escape in Clear Cell Renal Cell Carcinoma: A Prognostic Model and Dual-Functional Biomarker PLOD2 for Immunotherapy Stratification. (PubMed, J Cancer)
    The HRS model provides a quantitative tool for immunotherapy stratification. Notably, high PLOD2 expression indicates tumor progression yet paradoxically associates with enhanced immunotherapy response through activation of immune escape pathways, thereby offering a potential therapeutic target for converting "cold tumors" into "hot tumors".
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2)
    1m
    Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)
    The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.
    Journal
    |
    TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)
    2ms
    Cancer-Associated Fibroblast-Centric Risk Model Predicts Immunotherapy Resistance in Pancreatic Cancer and Reveals PLOD2 as a Key Stromal Therapeutic Target. (PubMed, Front Biosci (Landmark Ed))
    This study provides insights into the molecular mechanisms underlying PAAD and establishes a theoretical foundation for the development of CAF-targeting therapeutic strategies.
    Journal • IO biomarker
    |
    COL22A1 (Collagen Type XXII Alpha 1 Chain) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • TGFBI (Transforming Growth Factor Beta Induced) • TGFB2 (Transforming Growth Factor Beta 2)
    |
    sorafenib
    2ms
    The role of PLOD family genes in liver hepatocellular carcinoma: from mechanisms to therapeutic potential. (PubMed, BMC Cancer)
    Our study demonstrates that PLOD1, PLOD2, and PLOD3 are significantly upregulated in LIHC and correlate with poor prognosis. The PLOD genes may serve as valuable biomarkers for diagnosis and prognosis in LIHC. Moreover, targeting PLOD genes could provide new therapeutic strategies to hinder tumor progression and metastasis in liver cancer.
    Journal
    |
    MIR503 (MicroRNA 503) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • MIR193A (MicroRNA 193a) • MIR195 (MicroRNA 195)
    4ms
    Prognostic biomarker and clinical significance of PLOD gene family in clear cell renal cell carcinoma. (PubMed, Front Oncol)
    This study underscores the pivotal role of the PLOD family in ccRCC pathogenesis through ECM remodeling, immune modulation, and therapy resistance. Our results support their utility as diagnostic and prognostic biomarkers, and acetaminophen may serve as a candidate for targeting PLOD-mediated pathways, providing a foundation for future preclinical and therapeutic investigations.
    Journal
    |
    PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2)
    4ms
    Targeting PLOD2 induces epithelioid differentiation and improves therapeutic response in sarcomatoid renal cell carcinoma. (PubMed, J Adv Res)
    Targeting PLOD2-mediated tumor plasticity represents a novel differentiation-inducing strategy to reprogram sRCC into therapy-responsive epithelioid states. The repurposing potential of minoxidil provides an immediate translatable strategy to improve clinical outcomes in this treatment-resistant malignancy.
    Journal
    |
    IFNA1 (Interferon Alpha 1) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2)
    |
    gemcitabine • doxorubicin hydrochloride • axitinib
    6ms
    LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer. (PubMed, Cancer Res)
    Mechanistically, enzalutamide-mediated inhibition of the androgen receptor (AR) led to upregulation of key glycolytic enzymes...Significantly, the antiviral agent paritaprevir could directly bind to LHX2, effectively suppressing neuroendocrine marker expression and tumor progression. These findings uncover a potential role for LHX2 in orchestrating NEPC development, offering putative therapeutic targets for treating this aggressive cancer phenotype and overcoming drug resistance.
    Journal
    |
    AR (Androgen receptor) • LDHA (Lactate dehydrogenase A) • DNMT1 (DNA methyltransferase 1) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2)
    |
    Xtandi (enzalutamide)
    7ms
    Hypoxic stimulation of DCLK1 transcription and alternative-promoter switching fuels tumor malignancy in clear cell renal cell carcinoma. (PubMed, Cell Death Dis)
    Our findings also showed that the hyperactivated PLOD2-DCLK1-L axis in ccRCC is correlated with a higher EMT signature and predicts an unfavorable prognosis in ccRCC patients, while disrupting this signaling by pharmacological targeting of DCLK1-L significantly attenuated cancer malignancy both in vitro and in vivo. These findings couple hypoxia signaling to oncogenic alternative switching and highlight DCLK1-L as a promising therapeutic target for hypoxic PLOD2-rich ccRCCs.
    Journal
    |
    EPAS1 (Endothelial PAS domain protein 1) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2)
    7ms
    A Notch signaling pathway-related gene signature: Characterizing the immune microenvironment and predicting prognosis in hepatocellular carcinoma. (PubMed, J Transl Int Med)
    The model demonstrated an accurate estimation of overall survival, revealing alterations in immune status and immunotherapy sensitivity among HCC patients with different risk scores. This study constructed a Notch signaling pathway-related prognostic model, offering valuable insights for the assessment of immune characteristics and immunotherapy responses in HCC patients.
    Journal • Gene Signature • IO biomarker
    |
    SPP1 (Secreted Phosphoprotein 1) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2)
    7ms
    CKAP4 and PLOD2 as novel prognostic biomarkers in hepatocellular carcinoma: a proteomics-driven risk stratification model. (PubMed, Front Cell Dev Biol)
    In conclusion, this study identified CKAP4 and PLOD2 as novel prognostic protein markers for HCC. The developed nomogram, integrating these molecular markers with AJCC stage, shows promise in predicting OS and stratifying risk in HCC patients.
    Journal
    |
    PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • CKAP4 (Cytoskeleton Associated Protein 4)